BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21281254)

  • 1. Threonine peptidases as drug targets against malaria.
    Tschan S; Mordmüller B; Kun JF
    Expert Opin Ther Targets; 2011 Apr; 15(4):365-78. PubMed ID: 21281254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteasome as a target to combat malaria: hits and misses.
    Krishnan KM; Williamson KC
    Transl Res; 2018 Aug; 198():40-47. PubMed ID: 30009761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmodium kinases as targets for new-generation antimalarials.
    Lucet IS; Tobin A; Drewry D; Wilks AF; Doerig C
    Future Med Chem; 2012 Dec; 4(18):2295-310. PubMed ID: 23234552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteases of malaria parasites: new targets for chemotherapy.
    Rosenthal PJ
    Emerg Infect Dis; 1998; 4(1):49-57. PubMed ID: 9452398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmodia express two threonine-peptidase complexes during asexual development.
    Mordmüller B; Fendel R; Kreidenweiss A; Gille C; Hurwitz R; Metzger WG; Kun JF; Lamkemeyer T; Nordheim A; Kremsner PG
    Mol Biochem Parasitol; 2006 Jul; 148(1):79-85. PubMed ID: 16616382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria.
    Li H; Bogyo M; da Fonseca PC
    FEBS J; 2016 Dec; 283(23):4238-4243. PubMed ID: 27286897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Support vector machine based prediction of P. falciparum proteasome inhibitors and development of focused library by molecular docking.
    Subramaniam S; Mehrotra M; Gupta D
    Comb Chem High Throughput Screen; 2011 Dec; 14(10):898-907. PubMed ID: 21843142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helicases - feasible antimalarial drug target for Plasmodium falciparum.
    Tuteja R
    FEBS J; 2007 Sep; 274(18):4699-704. PubMed ID: 17824956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimalarial drugs and drug targets specific to fatty acid metabolic pathway of Plasmodium falciparum.
    Qidwai T; Khan F
    Chem Biol Drug Des; 2012 Aug; 80(2):155-72. PubMed ID: 22487082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.
    Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.
    Zhan W; Zhang H; Ginn J; Leung A; Liu YJ; Michino M; Toita A; Okamoto R; Wong TT; Imaeda T; Hara R; Yukawa T; Chelebieva S; Tumwebaze PK; Lafuente-Monasterio MJ; Martinez-Martinez MS; Vendome J; Beuming T; Sato K; Aso K; Rosenthal PJ; Cooper RA; Meinke PT; Nathan CF; Kirkman LA; Lin G
    Angew Chem Int Ed Engl; 2021 Apr; 60(17):9279-9283. PubMed ID: 33433953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimalarial drug therapy: the role of parasite biology and drug resistance.
    Daily JP
    J Clin Pharmacol; 2006 Dec; 46(12):1487-97. PubMed ID: 17101748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-cell in vitro screening for gametocytocidal compounds.
    Lucantoni L; Avery V
    Future Med Chem; 2012 Dec; 4(18):2337-60. PubMed ID: 23234555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure- and function-based design of Plasmodium-selective proteasome inhibitors.
    Li H; O'Donoghue AJ; van der Linden WA; Xie SC; Yoo E; Foe IT; Tilley L; Craik CS; da Fonseca PC; Bogyo M
    Nature; 2016 Feb; 530(7589):233-6. PubMed ID: 26863983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arresting malaria parasite egress from infected red blood cells.
    Lee MC; Fidock DA
    Nat Chem Biol; 2008 Mar; 4(3):161-2. PubMed ID: 18277974
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasmodium falciparum proteases as new drug targets with special focus on metalloproteases.
    Mahanta PJ; Lhouvum K
    Mol Biochem Parasitol; 2024 Jun; 258():111617. PubMed ID: 38554736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmodium falciparum signal peptide peptidase is a promising drug target against blood stage malaria.
    Li X; Chen H; Bahamontes-Rosa N; Kun JF; Traore B; Crompton PD; Chishti AH
    Biochem Biophys Res Commun; 2009 Mar; 380(3):454-9. PubMed ID: 19174148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Working in concert: the metalloaminopeptidases from Plasmodium falciparum.
    McGowan S
    Curr Opin Struct Biol; 2013 Dec; 23(6):828-35. PubMed ID: 23948130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. That was then but this is now: malaria research in the time of an eradication agenda.
    Kappe SH; Vaughan AM; Boddey JA; Cowman AF
    Science; 2010 May; 328(5980):862-6. PubMed ID: 20466924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial localization of the threonine peptidase PfHslV, a ClpQ ortholog in Plasmodium falciparum.
    Tschan S; Kreidenweiss A; Stierhof YD; Sessler N; Fendel R; Mordmüller B
    Int J Parasitol; 2010 Nov; 40(13):1517-23. PubMed ID: 20561525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.